February 05, 2025

FDA Approves Tocilizumab Biosimilar

FDA approves AVTOZMA after phase III trial confirms equivalence in efficacy, safety, and pharmacokinetics for RA and other inflammatory conditions.

Conexiant

February 03, 2025

FDA Monthly Round-Up: Key January Updates

January's FDA approvals include therapeutic advancements across neurology, oncology, pain management, and more.

Conexiant

January 27, 2025

Long-Term Effects of COVID-19 Reinfections

“Each subsequent infection could potentially increase the burden on the immune system, leaving individuals vulnerable to the cumulative effects of the virus."

Conexiant

January 27, 2025

CIA Shifts Stance on COVID-19 Origins

"Now, the most important thing is to make China pay for unleashing a plague on the world."

Conexiant

January 23, 2025

States Split on Immigration, Hospitals Adapt

“You are instilling fear into folks who may defer care, who may go without care, whose children may not get the vaccines they need, who may not be able to get treatment for an ear infection or surgery."

KFF Health News

June 20, 2024

FDA Proposes Removal of Switching Study Requirement for Biosimilars

Explore the FDA's proposed changes for biosimilar drugs and their interchangeability, including expert insights on regulatory impacts and market dynamics.

Reuters

September 30, 2024

Lupus Treatment Trial Paused Following Patient Deaths

Three of the fatalities showed a common pattern of symptoms and the deaths happened close to the time of dosing, while a non-fatal adverse event showed a similar proximity to dosing.

Reuters

June 12, 2024

USPSTF Releases Draft Osteoporosis Screening Guidelines

The USPSTF's draft recommendations reaffirm osteoporosis screening for older women, call for more research on screening men, and address health disparities.

Conexiant

January 15, 2025

Bertagnolli to Exit NIH Director Role

NIH director, Dr. Monica M. Bertagnolli, is stepping down after launching major initiatives in women's health and long COVID research, indicating optimism for their continuation under new leadership.

Conexiant